Navigation Links
Lentigen Awarded Phase I STTR Grant for Hunter Syndrome

GAITHERSBURG, Md., May 18 /PRNewswire/ -- Lentigen Corporation, a biotechnology company specializing in the development and manufacture of lentiviral gene delivery technologies, announced today that it has received a National Institutes of Health (NIH) small business technology transfer (STTR) grant for a program on "Lentiviral Gene Therapy for Mucopolysaccharidosis." In this program, Lentigen will collaborate with Dr. R. Scott McIvor Professor, Department of Genetics, Cell Biology and Development, and Dr. Walter Low, Professor, Departments of Neurosurgery and Physiology at the University of Minnesota, Minneapolis, MN.

Hunter syndrome (Mucopolysaccharidosis type II, MPS II) is a rare X-linked recessive, inherited lysosomal storage disorder with an onset at 2-4 years of age.  It has been estimated to affect approximately 1 in 155,000 live male births.  It is caused by the absence of iduronate-2-sulfatase, resulting in systemic accumulation of glycosaminoglycans. Affected individuals suffer from skeletal abnormalities, organomegaly, life-threatening obstructive airway disease, and, in the severely enzyme deficient form, neurologic degeneration and death by age 15. The University of Minnesota is a world-leading center for the treatment of lysosomal storage diseases by hematopoietic stem cell transplantation.

The goal of this program is to evaluate the feasibility of using lentiviral vectors to restore the missing gene in patient's cells and return the cells back to the patient.  The specific research that will be conducted under this grant will use a mouse model of MPS II created in the laboratory of Dr. Joseph Muenzer, University of North Carolina, to establish and test conditions for introduction of the correcting gene and its effectiveness when reintroduced into the animals.

"The demonstrated safety and effectiveness of lentiviral vectors to mediate gene transfer into hematopoietic stem cells and provide clinical benefit in patients with Adrenoleukodystrophy (Lorenzo Oil's disease), as reported in the journal Science in November 2009, makes them the vector of choice for this application" stated Dr. Boro Dropulic, Lentigen's President and Chief Scientific Officer.  "This project is consistent with our strategy of applying Lentigen's technology in diseases of high unmet therapeutic need."

About Lentigen Corporation

Lentigen Corporation is a privately owned biotechnology company focused on the development of lentiviral vector technology for a wide range of therapeutic, vaccine, and bioproduction applications. Lentiviral vectors are the most efficient vehicles for the delivery of genes or gene silencing sequences stably into cells. Lentigen is a highly collaborative company, co-developing Lentiviral vector-based products across a broad spectrum of bench to clinical applications. Collaborations include The National Institutes of Health, PATH, IAVI, Harvard Medical School, Expression Therapeutics, Epixis SA, The University of Pennsylvania, The Johns Hopkins University, Case Western Reserve University, The Medical College of South Carolina, The University of Pittsburgh and The U.S. Army. For further information, visit

SOURCE Lentigen Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. VIRxSYS and Lentigen Announce Litigation Settlement
2. Lentigen Appoints Tim Ravenscroft as Chief Executive Officer
3. Lentigen to Move Headquarters and Manufacturing to Gaithersburg
4. Lentigen Corporation Announces Exclusive Licensing Agreement With Case Western Reserve University to Develop Novel Stem-Cell Therapy for Brain Cancer
5. Lentigen Licenses Fundamental Lentiviral Vector Technology Patent From the University of Cambridge
6. Lentigen Corporation Receives Four Research Grants From the National Institutes of Health
7. Lentigen Appoints Jim Meade as Vice President of Corporate Development
8. Lentigen Corporation Announces Relocation to New Facility
9. Lentigen Corporation and PATH Announce Partnership on Innovative Vaccine for Pandemic Influenza
10. Lentigen and Expression Therapeutics Sign Hemophilia Co-Development Agreement
11. GeneNews CSO Dr. CC Liew awarded state honour by the Government of Malaysia
Post Your Comments:
(Date:6/23/2016)... Md. , June 23, 2016 A person ... from the crime scene to track the criminal down. ... the U.S. Food and Drug Administration (FDA) uses DNA evidence ... Sound far-fetched? It,s not. The FDA ... sequencing to support investigations of foodborne illnesses. Put as simply ...
(Date:6/23/2016)... SAN FRANCISCO , June 23, 2016   ... it has secured $1 million in debt financing from ... to ramp up automation and to advance its drug ... for its new facility. "SVB has been ... goes beyond the services a traditional bank would provide," ...
(Date:6/23/2016)... , June 23, 2016  Blueprint Bio, a ... discoveries to the medical community, has closed its Series ... Matthew Nunez . "We have received a ... the capital we need to meet our current goals," ... provide us the runway to complete validation on the ...
(Date:6/23/2016)... ... June 23, 2016 , ... Velocity Products, a division ... tuned and optimized exclusively for Okuma CNC machining centers at The International Manufacturing ... collaboration among several companies with expertise in toolholding, cutting tools, machining dynamics and ...
Breaking Biology Technology:
(Date:6/2/2016)... Perimeter Surveillance & Detection Systems, ... Infrastructure, Support & Other Service  The latest ... comprehensive analysis of the global Border Security market ... of $17.98 billion in 2016. Now: In ... in software and hardware technologies for advanced video surveillance. ...
(Date:5/24/2016)... Calif. , May 24, 2016 Ampronix facilitates superior patient care by ... LMD3251MT  3D medical LCD display is the latest premium product recently added to the ... ... ... Sony 3d Imaging- LCD Medical Display- Ampronix News ...
(Date:5/16/2016)... --  EyeLock LLC , a market leader of iris-based ... IoT Center of Excellence in Austin, Texas ... embedded iris biometric applications. EyeLock,s iris authentication ... with unmatched biometric accuracy, making it the most proven ... platform uses video technology to deliver a fast and ...
Breaking Biology News(10 mins):